Trial Profile
A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.